F7 Antibody / Factor VII

Overview

Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin and Factors X, IX, V and VIII), which are involved in a blood coagulation cascade that leads to the formation of insoluble Fibrin clots and the promotion of platelet aggregation. Coagulation Factor VII (serum prothrombin conversion accelerator, proconvertin, F7, Factor VII) is a 406 amino acid, vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor. Factor IX A, Factor X A, Factor XII A or Thrombin-mediated proteolytic cleavage of Factor VII at Arg 152-Ile 153 generates Factor VII A, an active serine protease composed of a catalytic heavy chain disulfide linked to a light chain, containing two EGF-like domains. Mutations at the F7 locus that lead to Factor VII deficiencies are generally asymptomatic or phenotypically uncharacterized, with hemorrhagic diathesis occurring at extremely low levels.

This anti-F7 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone F7/3516, Mouse IgG2a, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.

Key elements and design rationale

• Target: F7
• Format: Purified
• Localization: Secreted, cytoplasm (mitochondria)
• Species reactivity: Human
• Applications (listed): ELISA, IHC-P
• Conjugate: Unconjugated
• Clone and antibody class: Monoclonal (mouse origin), clone F7/3516, Mouse IgG2a, kappa

Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.

Biological background

F7 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.

Research relevance and current trends

• Profiling F7 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
• Combining antibody-based detection with multi-omics or imaging readouts to link F7 signal with phenotype.
• Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.

Common research applications

• ELISA
• IHC-P

Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.

Notes for experimental interpretation

• Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
• Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
• Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.